These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 29079451)
21. Novel GPR119 agonist AS1669058 potentiates insulin secretion from rat islets and has potent anti-diabetic effects in ICR and diabetic db/db mice. Oshima H; Yoshida S; Ohishi T; Matsui T; Tanaka H; Yonetoku Y; Shibasaki M; Uchiyama Y Life Sci; 2013 Feb; 92(2):167-73. PubMed ID: 23246743 [TBL] [Abstract][Full Text] [Related]
22. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function. Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M Diabetes Obes Metab; 2011 Jan; 13(1):34-41. PubMed ID: 21114601 [TBL] [Abstract][Full Text] [Related]
23. Lysophosphatidylcholine elicits intracellular calcium signaling in a GPR55-dependent manner. Drzazga A; Sowinska A; Krzeminska A; Rytczak P; Koziolkiewicz M; Gendaszewska-Darmach E Biochem Biophys Res Commun; 2017 Jul; 489(2):242-247. PubMed ID: 28552522 [TBL] [Abstract][Full Text] [Related]
24. The therapeutic potential of GPR119 agonists for type 2 diabetes. Ohishi T; Yoshida S Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451 [TBL] [Abstract][Full Text] [Related]
25. The significance of GPR119 agonists as a future treatment for type 2 diabetes. Dhayal S; Morgan NG Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393 [TBL] [Abstract][Full Text] [Related]
26. β-Cell Inactivation of Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842 [TBL] [Abstract][Full Text] [Related]
27. The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119. Stone VM; Dhayal S; Smith DM; Lenaghan C; Brocklehurst KJ; Morgan NG Br J Pharmacol; 2012 Apr; 165(8):2758-70. PubMed ID: 22029844 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the insulin-releasing and glucose-lowering effects of GPR120 activation in pancreatic β-cells. Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM Diabetes Obes Metab; 2014 Nov; 16(11):1128-39. PubMed ID: 24919766 [TBL] [Abstract][Full Text] [Related]
29. Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder. Zhang S; Ma Y; Li J; Ma J; Yu B; Xie X Proc Natl Acad Sci U S A; 2014 Oct; 111(40):14571-6. PubMed ID: 25246581 [TBL] [Abstract][Full Text] [Related]
31. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus]. Matsumoto K; Yoshitomi T; Shimada T Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729 [TBL] [Abstract][Full Text] [Related]
32. 20-HETE promotes glucose-stimulated insulin secretion in an autocrine manner through FFAR1. Tunaru S; Bonnavion R; Brandenburger I; Preussner J; Thomas D; Scholich K; Offermanns S Nat Commun; 2018 Jan; 9(1):177. PubMed ID: 29330456 [TBL] [Abstract][Full Text] [Related]
34. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. Lan H; Vassileva G; Corona A; Liu L; Baker H; Golovko A; Abbondanzo SJ; Hu W; Yang S; Ning Y; Del Vecchio RA; Poulet F; Laverty M; Gustafson EL; Hedrick JA; Kowalski TJ J Endocrinol; 2009 May; 201(2):219-30. PubMed ID: 19282326 [TBL] [Abstract][Full Text] [Related]
35. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. de Leeuw van Weenen JE; Parlevliet ET; Maechler P; Havekes LM; Romijn JA; Ouwens DM; Pijl H; Guigas B Biochem Pharmacol; 2010 Jun; 79(12):1827-36. PubMed ID: 20138024 [TBL] [Abstract][Full Text] [Related]
36. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus. Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996 [TBL] [Abstract][Full Text] [Related]
37. Lysophosphatidylcholine and lysophosphatidylinosiol--novel promissing signaling molecules and their possible therapeutic activity. Drzazga A; Sowińska A; Koziołkiewicz M Acta Pol Pharm; 2014; 71(6):887-99. PubMed ID: 25745761 [TBL] [Abstract][Full Text] [Related]
38. Synthesis and glucose-stimulate insulin secretion (GSIS) evaluation of vindoline derivatives. Xiao C; Tian Y; Lei M; Chen F; Gan X; Yao X; Shen X; Chen J; Hu L Bioorg Med Chem Lett; 2017 Mar; 27(5):1316-1318. PubMed ID: 28162858 [TBL] [Abstract][Full Text] [Related]